{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:53:42Z","timestamp":1791035622893,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,7,4]],"date-time":"2005-07-04T00:00:00Z","timestamp":1120435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The clinical and pathological characteristics and the clinical course of patients with breast cancer and BRCA 1\u20132 mutation are poorly known.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From 1997, patients with breast cancer and a family history of breast or ovarian cancer were offered BRCA testing. The clinical and pathological features of patients with known BRCA status were retrospectively assessed and comparisons were made between cancers arising in BRCA positive and BRCA wild type (WT) patients respectively. Type of treatment, pattern of relapse, event (local relapse, contralateral breast cancer, metastases) free and overall survival were also compared in the two groups. Out of the 210 patients tested, 125 had been treated and followed-up at our Institution and were evaluated in this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>BRCA positive patients tended to be more often premenopausal (79% vs 65%) and to have positive lymphnodes (63% vs 49%), poorly differentiated tumours (76% vs 40% \u2013 p = 0.002 at univariate analysis, not significant at multivariate analysis) and negative estrogen receptors (43% vs 29%). Treatment was not different in the two groups. In the 86 BRCA-WT patients, the first event was a local relapse in 3 (3%), metachronous contralateral breast cancer in 7 (8%) and distant metastases in 16 (19%). In the 39 BRCA positive patients, the corresponding figures were 3 (8%), 8 (21%) and 3 (8%). There was no difference in event free survival, with a median of 180 months in both groups of patients. At 20 years, projected survival was 85% for BRCA positive patients and 55% for BRCA-WT, but this difference was not statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Although BRCA positive patients have more frequently negative prognostic factors, their prognosis appears to be equal to or better than in patients with BRCA-WT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-5-70","type":"journal-article","created":{"date-parts":[[2005,7,5]],"date-time":"2005-07-05T08:10:24Z","timestamp":1120551024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Familial breast cancer: characteristics and outcome of BRCA 1\u20132 positive and negative cases"],"prefix":"10.1186","volume":"5","author":[{"given":"Andrea","family":"Veronesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia de","family":"Giacomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Dolcetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Viel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Crivellari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Bidoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Boiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,7,4]]},"reference":[{"key":"258_CR1","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1998.16.5.1969","volume":"16","author":"MA Blackwood","year":"1998","unstructured":"Blackwood MA, Weber BL: BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998, 16: 1969-1977.","journal-title":"J Clin Oncol"},{"key":"258_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5","volume":"18","author":"PO Chappuis","year":"2000","unstructured":"Chappuis PO, Nethercot V, Foulkes WD: Clinico-pathological characteristics of BRCA-1 and BRCA-2 related breast cancer. Semin Surg Oncol. 2000, 18: 287-295. 10.1002\/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5.","journal-title":"Semin Surg Oncol"},{"key":"258_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/1097-0142(19820715)50:2<360::AID-CNCR2820500233>3.0.CO;2-4","volume":"50","author":"W Albano","year":"1982","unstructured":"Albano W, Recabaren J, Lynch H: Natural history of hereditary cancer of the breast and colon. Cancer. 1982, 50: 360-363.","journal-title":"Cancer"},{"key":"258_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/1097-0142(19860715)58:2<360::AID-CNCR2820580227>3.0.CO;2-F","volume":"58","author":"D Andersson","year":"1986","unstructured":"Andersson D, Badzioch M: Survival in familial breast cancer patients. Cancer. 1986, 58: 360-365.","journal-title":"Cancer"},{"key":"258_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1012203917104","volume":"69","author":"J Chang","year":"2001","unstructured":"Chang J, Elledge RM: Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat. 2001, 69: 101-113. 10.1023\/A:1012203917104.","journal-title":"Breast Cancer Res Treat"},{"key":"258_CR6","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/cncr.11688","volume":"98","author":"WD Foulkes","year":"2003","unstructured":"Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, B\u00e9gin LR, Brunet J-S, Narod SA: Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA-1 related breast carcinoma. Cancer. 2003, 98: 1569-1577. 10.1002\/cncr.11688.","journal-title":"Cancer"},{"key":"258_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1023\/A:1008340723974","volume":"11","author":"WD Foulkes","year":"2000","unstructured":"Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F: Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol. 2000, 11: 307-313. 10.1023\/A:1008340723974.","journal-title":"Ann Oncol"},{"key":"258_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(05)79248-5","volume":"352","author":"Y Ansquer","year":"1998","unstructured":"Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D: Survival in early-onset BRCA1 breast cancer patients: Institute Curie Breast Cancer Group. Lancet. 1998, 352: 541-10.1016\/S0140-6736(05)79248-5.","journal-title":"Lancet"},{"key":"258_CR9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/S0140-6736(02)08434-9","volume":"359","author":"BG Haffty","year":"2002","unstructured":"Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M: Outcome of conservatively managed early-onset breast cancer by BRCA 1\/2 status. Lancet. 2002, 359: 1471-1477. 10.1016\/S0140-6736(02)08434-9.","journal-title":"Lancet"},{"key":"258_CR10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.1998.16.2.397","volume":"16","author":"OT Johannsson","year":"1998","unstructured":"Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 1998, 16: 397-404.","journal-title":"J Clin Oncol"},{"key":"258_CR11","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.1999.17.11.3396","volume":"17","author":"LG Verhhoog","year":"1999","unstructured":"Verhhoog LG, Brekelmans CTM, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, Tilanus-Linthorst MM, Wagner A, Devilee P, Halley DJ, van den Ouweland AM, Meijers-Heijboer EJ, Klijn JG: Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999, 17: 3396-3402.","journal-title":"J Clin Oncol"},{"key":"258_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/ijc.1341","volume":"93","author":"H Eerola","year":"2001","unstructured":"Eerola H, Vahteristo P, Sarantaus L, Kyyronen P, Pirhonen S, Blomqvist C, Pukkala E, Nevanlinna H, Sankila R: Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1\/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer. 2001, 93: 368-372. 10.1002\/ijc.1341.","journal-title":"Int J Cancer"},{"key":"258_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1053\/ctrv.2001.0233","volume":"27","author":"MO Nicoletto","year":"2001","unstructured":"Nicoletto MO, Donach M, De Nicolo A, Artioli G, Banna G, Monfardini S: BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. Cancer Treatment Reviews. 2001, 27: 295-304. 10.1053\/ctrv.2001.0233.","journal-title":"Cancer Treatment Reviews"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-70.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-5-70\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-70","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-5-70.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:45:46Z","timestamp":1630446346000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-5-70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,4]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-5-70","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,4]]},"assertion":[{"value":"17 January 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"70"}}